HLA-A*02 allele expression might not only predict better survival but also indicate enhanced tumor antigen presentation, potentially aiding in selecting patients with HNSCC for T-cell-dependent immunotherapies (122). This evidence concerns the gene HLA-A and head and neck squamous cell carcinoma.